Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pelareorep - Oncolytics Biotech

Next Previous
Drug Profile

Pelareorep - Oncolytics Biotech

Alternative Names: AN-1004; PO-BB0209; REOLYSIN; Reosyn; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus; Wild-type reovirus - Oncolytics Biotech

Latest Information Update: 12 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncolytics Biotech
  • Developer Adlai Nortye; Canadian Cancer Society Research Institute; Mayo Clinic; National Cancer Institute (USA); Oncolytics Biotech; PrECOG; Roche; University of Leeds; University of Southern California
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Peritoneal cancer; Ovarian cancer; Gastric cancer; Pancreatic cancer; Adenocarcinoma; Fallopian tube cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer; Head and neck cancer
  • Phase II Adenocarcinoma; Brain cancer; Colorectal cancer; Fallopian tube cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Sarcoma
  • Phase I/II Anal cancer; Glioma; Multiple myeloma; Pancreatic cancer
  • No development reported Acute myeloid leukaemia; Glioblastoma; Liver cancer; Solid tumours

Most Recent Events

  • 04 May 2026 Oncolytics Biotech engages with US FDA to discuss a potential accelerated approval pathway in RAS-Mutant microsatellite-stable metastatic colorectal cancer in second line setting
  • 04 May 2026 Efficacy data from a phase I trial in Colorectal cancer released by Oncolytics Biotech
  • 27 Apr 2026 Oncolytics Biotech conducted type C meeting with the US FDA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top